This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Evidence-Based Medicine  • Prognosis/ Outcomes  • Psoriasis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Jonathan M. Batchelor, BMedSci, BM BS, MRCP(UK); John R. Ingram, DM, MRCP(UK); Hywel Williams, MSc, PhD, FRCP

Arch Dermatol. 2009;145(6):704-706.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
Saurat JH, Stingl G, Dubertret L, et al
Br J Dermatol. 2008;158(3):558-566

Question: How effective and safe is adalimumab compared with methotrexate in patients with moderate to severe psoriasis?

Design: Noninferiority randomized controlled trial.

Setting: Multicenter trial performed in hospitals in Europe and Canada.

Participants: A total of 271 patients with moderate to severe psoriasis were randomized. Moderate to severe psoriasis was defined as affecting 10% or more of the body surface area and giving a Psoriasis Area and Severity Index (PASI) of 10 or higher. All patients were naive to tumor necrosis factor (TNF)–antagonist therapies and to methotrexate. Fifteen patients were lost to follow-up after randomization, and 256 . . . [Full Text of this Article]

COMMENT


AUTHOR INFORMATION
Department of Dermatology, Addenbrooke's Hospital, Cambridge, England (Dr Batchelor); Department of Dermatology, University Hospital of Wales, Heath Park, Cardiff (Dr Ingram); Centre of Evidence-Based Dermatology, University of Nottingham, King's Meadow Campus, Nottingham, England (Dr Williams)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Adalimumab vs Methotrexate for the Treatment of Chronic Plaque Psoriasis—Reply
Jean-Hilaire Saurat
Arch Dermatol. 2009;145(6):706.
EXTRACT | FULL TEXT